寶齡富錦 News Releases

【TaiGen Biotech】Company to Participate in SinoPac Securities' Investor Briefing on June 25, 2026

TaiGen Biotech has been invited to attend the investor briefing hosted by SinoPac Securities on June… · 2026-06-23

【PBF Inc.】February 2026 Monthly Revenue NT$233 Million (YoY -4.5%)

PBF Inc. (1760) announced its February 2026 monthly revenue as NT$233 million, a year-on-year decrea… · 2026-02-01

[Paolyta] Announcement regarding the signing of an authorization agreement for the new drug Nephoxil (Ferric Citrate Capsules) in Mainland China

Paolyta Co., Ltd. announced that its board has approved the signing of an authorization agreement fo… · 2026-06-05

[PBF] Announcement of the Lifting of Non-Compete Restrictions for Directors

PBF announced that the Annual General Meeting held on May 25, 115, approved the lifting of non-compe… · 2026-05-25

[PB Pharmaceuticals] Announcement of Cash Dividend Distribution

PB Pharmaceuticals announced a cash dividend distribution of NT$2 per share, consisting of NT$1.8 fr… · 2026-05-25

[PBF] Announcement of Important Resolutions from the 115 Annual General Meeting

PBF held its Annual General Meeting on May 25, 115, approving the 114th-year earnings distribution, … · 2026-05-25

[Paion] Ferric Citrate, the Active Ingredient for Kidney Disease Drug, Approved for Market Entry in China by NMPA

Paion Biotech announced that the Chinese National Medical Products Administration (NMPA) has approve… · 2026-05-21

BaoLing FuJin Announces March 2026 Revenue of 150 Million JPY (+17.1% Year-over-Year)

BaoLing FuJin reported March 2026 revenue of 150 million JPY, a 17.1% increase year-over-year. This … · 2026-03-01

[Pao Feng Biotechnology] May 2026 Revenue Reaches NT$234 Million (YoY +1.8%)

Pao Feng Biotechnology (1760) announced its revenue for May 2026, reaching NT$234 million (234,475 t… · 2026-05-01

[Baoling Fujin] Announcement: The company's board of directors approved the Q1 2026 consolidated financial report.

Baoling Fujin's board of directors approved the consolidated financial report for the first quarter … · 2026-05-12

Bionime Corporation: April 2026 Monthly Revenue Reaches TWD 145 Million (YoY +7.0%)

Bionime Corporation announced its April 2026 monthly revenue reached TWD 145 million, marking a 7.0%… · 2026-04-01

【Bao Ling Fu Jin】Announcement of the Board Meeting Date for the Company's Q1 2026 Financial Report on May 12, 2026

Bao Ling Fu Jin has announced that its Board of Directors will convene on May 12, 2026, to review an… · 2026-05-04

[PBF] The company's new kidney disease drug Nephoxil approved for marketing in China

PBF Biotechs' Nephoxil 500mg Capsule has received approval from China's NMPA for controlling hyperph… · 2026-04-27

BaoLing FuJin Announces March 2026 Revenue of 150 Million JPY (+17.1% Year-over-Year)

BaoLing FuJin reported March 2026 revenue of 150 million JPY, a 17.1% increase year-over-year. This … · 2026-03-01

【PBF Inc.】February 2026 Monthly Revenue NT$233 Million (YoY -4.5%)

PBF Inc. (1760) announced its February 2026 monthly revenue as NT$233 million, a year-on-year decrea… · 2026-02-01

Bionime Corporation: April 2026 Monthly Revenue Reaches TWD 145 Million (YoY +7.0%)

Bionime Corporation announced its April 2026 monthly revenue reached TWD 145 million, marking a 7.0%… · 2026-04-01

[PBF] The company's new kidney disease drug Nephoxil approved for marketing in China

PBF Biotechs' Nephoxil 500mg Capsule has received approval from China's NMPA for controlling hyperph… · 2026-04-27

【Bao Ling Fu Jin】Announcement of the Board Meeting Date for the Company's Q1 2026 Financial Report on May 12, 2026

Bao Ling Fu Jin has announced that its Board of Directors will convene on May 12, 2026, to review an… · 2026-05-04

[Baoling Fujin] Announcement: The company's board of directors approved the Q1 2026 consolidated financial report.

Baoling Fujin's board of directors approved the consolidated financial report for the first quarter … · 2026-05-12